Cathepsin G (CG), a neutrophil serine protease, induces cell migration and multicellular aggregation of human breast cancer MCF-7 cells in a process that is dependent on E-cadherin and CG enzymatic activity. While these tumor cell aggregates can cause tumor emboli that could represent intravascular growth and extravasation into the surrounding tissues, resulting in metastasis, the molecular mechanism underlying this process remains poorly characterized. In this study, we aimed to identify the signaling pathway that is triggered during CG-mediated stimulation of cell aggregation. Screening of a library of compounds containing approximately 90 molecular-targeting drugs revealed that this process was suppressed by the insulin-like growth factor-1 (IGF-1) receptor (IGF-1R)-specific kinase inhibitor OSI-906, as well as the multikinase inhibitors axitinib and sunitinib. Antibody array analysis, which is capable of detecting tyrosine phosphorylation of 49 distinct receptor tyrosine kinases, and the results of immunoprecipitation studies indicated that IGF-1R is phosphorylated in response to CG treatment. Notably, IGF-1R neutralization via treatment with a specific antibody or silencing of IGF-1R expression through siRNA transfection suppressed cell aggregation. Furthermore, CG treatment of MCF-7 cells resulted in increased release of IGF-1 into the medium for 24 h, while antibody-mediated IGF-1 neutralization partially prevented CG-induced cell aggregation. These results demonstrate that autocrine IGF-1 signaling is partly responsible for the cell aggregation induced by CG.
T umor invasion and metastasis frequently occur in conjunction with inflammation and leukocyte infiltration in the tumor mass. (1, 2) Neutrophils that infiltrate the tumor mass, referred to as tumor-associated neutrophils (TAN), have been widely suggested to both suppress and promote cancer-cell proliferation and metastasis. (3) (4) (5) (6) Specifically, TAN that present the antitumor phenotype (N1-type TAN) secrete immune-activating cytokines and chemokines, and produce reactive oxygen species, which kill the tumor cells, while N2-type TAN promote the proliferation and migration of cancer cells through the secretion of growth factors, cytokines and chemokines. Moreover, N2-type TAN secrete proteases, such as matrix metalloproteinase-9 (MMP-9), that digest the extracellular matrix (ECM) and thereby facilitate the dissemination of cancer cells into the surrounding tissues, as well as the intra/extravasation of these cells. Infiltration of neutrophils into the tumor mass indicates poor prognosis in several types of tumors. (6) Neutrophils, which play an essential role in the innate immune system, engulf pathogens and secrete proteases stored in azurophil granules for the digestion of pathogens within the blood. (7) (8) (9) (10) Azurophil proteases such as cathepsin G (CG) and neutrophil elastase (NE) have also been widely suggested to be associated with the aggravation of tumor development by TAN. NE was reported to accelerate tumor cell proliferation in both a loxP-Stop-loxP K-ras G12D model of lung adenocarcinoma and the lung-cancer cell line A549. (11) Elevated levels of NE facilitate tumor invasion and metastasis through degradation of the ECM; (12, 13) accordingly, NE levels appear to correlate with poor prognosis in breast cancer. (14) In contrast to NE, the function of CG in tumor pathology remains unclear.
Cathepsin G is a serine protease secreted from activated neutrophils and a subset of monocytes. (8, 9, 15, 16) Unlike other neutrophil proteases, CG exhibits chymotrypsin-like and trypsin-like substrate specificity, as well as a preference for large hydrophobic (Phe, Leu and Met) and positive (Lys and Arg) P 1 residues, when using synthetic peptides as a substrate. (17) (18) (19) (20) Moreover, CG also influences hormone activation, apoptosis, chemotaxis, blood coagulation and cardiomyocyte anoikis. (21) (22) (23) (24) We previously showed that CG induces cell migration, followed by the formation of 3D-homotypic and multicellular aggregates, through E-cadherin-dependent cellcell adhesion in human breast cancer MCF-7 cells. (25, 26) The morphological and biological properties of the CG-induced spheroids resemble those of tumor emboli observed in the lymphatic vessels of patients with inflammatory breast carcinoma. (27, 28) Because tumor-cell aggregates can cause emboli in blood and lymphatic vessels, followed by intravascular and secondary growth in target organs, these findings suggest that CG could function as a metastasis-promoting factor. With respect to the molecular mechanism of CG-induced cell aggregation, we have shown that this process occurs in a CG enzymatic activity-dependent and protease-activated receptors (PARs)-independent manner. (29) Furthermore, CG-induced cell aggregation does not solely involve the degradation of ECM, such as fibronectin. (30) These results clearly indicate that activation of intracellular signaling is involved in the stimulation of cell motility and the observed aggregation of MCF-7 cells. However, the molecular underpinnings of CG-induced cell aggregation, such as the binding target, proteolytic substrate and intracellular signaling pathway activated by CG, remain incompletely elucidated.
In this study, we demonstrate that CG-induced aggregation of MCF-7 cells is suppressed by multikinase inhibitors and by an insulin-like growth factor-1 (IGF-1) receptor (IGF-1R)-specific inhibitor. Whereas CG stimulation evoked IGF-1R signaling, blockage of IGF-1R through treatment with neutralizing antibodies or siRNA hindered cell aggregation. Moreover, treatment of MCF-7 cells with CG resulted in elevated IGF-1 release. Therefore, we conclude that IGF-1 signaling is responsible for the cell aggregation induced by CG.
Materials and Methods
Reagents. The following reagents were obtained from commercial sources: CG purified from human neutrophils (95% purity; BioCentrum, Krak ow, Poland); anti-Akt rabbit polyclonal antibodies, anti-phospho Akt (S473) rabbit monoclonal antibodies (clone D9E), anti-phospho Erk1/2 (Erk1: pT202/ pY204; Erk2: pT185/pY187) rabbit monoclonal antibodies (clone D13.14.4E), and anti-IGF-1R b-subunit rabbit monoclonal antibodies (clone D23H3) (Cell Signaling Technology, Danvers, MA, USA); anti-Erk1/2 rabbit polyclonal and anti-IGF-1 rabbit polyclonal antibodies (Abcam, Cambridge, UK); anti-phosphotyrosine mouse monoclonal antibodies (clone 4G10; Merck Millipore, Darmstadt, Germany); anti-b-actin mouse monoclonal antibodies (clone AC-15; Sigma-Aldrich, St. Louis, MO, USA); and anti-IGF-1R a-subunit mouse monoclonal antibodies (clone #33255, R&D Systems, Minneapolis, MN, USA). The Screening Committee of Anticancer Drugs (SCADS) Inhibitor Kit was supplied by SCADS, supported by a Grant-in-Aid for Scientific Research on Innovative Areas, Scientific Support Programs for Cancer Research, from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. OSI-906 and axitinib were purchased from Shelleck Chemicals (Houston, TX, USA) and Merck Millipore, respectively, while sorafenib, sunitinib and vandetanib were purchased from Cayman Chemicals (Ann Arbor, MI, USA). Pazopanib and recombinant human IGF-1 were obtained from SYNkinase (Parkville VIC, Australia) and Wako Pure Chemical (Osaka, Japan), respectively.
Cell culture. Human breast cancer MCF-7 cells were kindly provided by Dr Hiroshi Kosano (Teikyo University, Japan), and were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated FBS (MP Biomedicals, Solon, OH, USA) and 80 lg/mL kanamycin (Wako Pure Chemical), as described previously. (30) MCF-7 cell-aggression assay. To quantitatively assess the degree of spheroid formation, we quantified cells that were tightly attached to culture plates after staining with crystal violet, as previously described. (25) Briefly, MCF-7 cells (1 9 10 4 cells/well) were seeded in 96-well plates in RPMI 1640 medium containing 5% FBS, and then washed with serum-free RPMI 1640 medium. After cultivation for 24 h, the cells were pre-cultured for 1 h in RPMI 1640 containing 1% BSA and the agents whose effects on CG-induced cell aggregation were to be tested. After pre-culturing, the cells were cultivated in the presence of purified CG (2.5 or 40 nM) for 24 h. Subsequently, the culture plates were vigorously tapped on paper towels 10 times to eliminate loosely attached cell spheroids, and the remaining cells were dried at room temperature and stained with 0.1% crystal violet in PBS for 10 min. Finally, the plates were extensively washed with tap water and dried at room temperature, the crystal violet within the residual cells was released via lysis with 100 lL of 0.5% SDS, and the optical density at 595 nm (OD 595 ) was measured using a microplate reader (ALVO X3; Perkin Elmer, Waltham, MA, USA).
Measurement of cathepsin G enzymatic activity. The enzymatic activity of CG was measured using N-succinyl-Ala-AlaPro-Phe p-nitroanilide (Sigma) as a substrate, as previously described. (17) One unit of enzyme represented the amount needed to hydrolyze 1.0 lmol of the substrate per minute at 37°C at pH 7.5. The release rate of 4-nitroanilide was analyzed based on OD 405 values, as measured using a microplate reader.
Western blotting. SDS-PAGE and subsequent western blotting analyses were performed as previously described. (29) Cell lysates were prepared by solubilizing cells in radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl [pH 7.5] containing 150 mM NaCl, 1% NP-40, and 0.1% sodium deoxycholate) supplemented with protease-inhibitor and phosphatase-inhibitor cocktails (Sigma). Samples were then mixed at a 1:4 ration with 5 9 sample buffer (300 mM Tris-HCl [pH 6.8] containing 10% 2-mercaptoethanol, 10% SDS, 50% glycerol and 0.05% Coomassie Brilliant Blue) and boiled for 5 min. The resulting samples (20 lg protein/lane) were subsequently separated by SDS-PAGE using pre-cast 5%-20% Trisglycine gradient gels (Atto Corporation, Tokyo, Japan) and transferred to PVDF membranes (Wako Pure Chemical). Membranes were blocked by incubation with TBS containing 0.1% Tween 20 (TBS-T) and 5% skim milk (Megmilk Snow Bland, Tokyo, Japan) or BSA (Sigma) for 1 h, probed with the appropriate primary antibodies diluted with Can Get Signal Immunoreaction Enhancer Solution (Toyobo, Osaka, Japan) at 4°C, washed extensively with TBS-T, and incubated with HRPconjugated secondary antibodies (1:5000 dilution) (GE Healthcare, Little Chalfont, UK). Finally, the membranes were washed, developed by incubation with ECL detection reagents (GE Healthcare) and exposed to Hyperfilm ECL (GE Healthcare).
Antibody array. Phosphorylation of receptor tyrosine kinases was comprehensively analyzed using Proteome Profiler Human Phospho-RTK arrays (R&D Systems), which are capable of detecting the phosphorylation of 49 receptor tyrosine kinases, according to the manufacturer's instructions. MCF-7 cells were seeded in RPMI 1640 containing 5% FBS and cultured for 24 h. The cells were then cultured overnight, after which the medium was replaced with RPMI 1640 containing 1% BSA for serum starvation and treated with purified CG for 5 or 15 min. Subsequently, cell lysates were prepared by solubilizing the cells (1 9 10 7 cells/mL) in the lysis buffer provided with the kit, but supplemented with a protease-inhibitor cocktail (Sigma) and subjected to Phospho-RTK array analysis (300 lg/array).
Immunoprecipitation. Whole-cell lysates were prepared by incubating cells with Pierce IP Lysis Buffer (Thermo Fisher Scientific, Waltham, MA, USA) for 15 min on ice. The lysates (500 lg) were then incubated with the anti-IGF-1R b-subunit antibody (5 lL) overnight at 4°C, following which the antibody was bound to Protein A-Sepharose (GE Healthcare) at 4°C for 1 h. After formation of the antibody-bead complex, the beads were washed thrice with lysis buffer, and the captured protein complex was eluted in 3 9 sample buffer (180 mM Tris-HCl [pH 6.8] containing 6% 2-mercaptoethanol, 6% SDS, 30% glycerol and 0.03% Coomassie Brilliant Blue). Eluates were analyzed by immunoblot using the anti-phosphotyrosine antibody.
Protein assay. Protein concentrations were determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific); BSA was used as the standard.
RNA interference. Silencer Select siRNA (IGF-1R siRNA; IDs: s7211 and s7212) were purchased from Thermo Fisher Scientific. The reverse-transfection procedure for MCF-7 cells was performed according to the manufacturer's instruction manual. The RNA duplex was first diluted with Opti-MEM (Thermo Fisher Scientific) to a final concentration of 5 nM, and then mixed with Lipofectamine RNAi MAX (Thermo Fisher Scientific). The cells and transfection mixture were added to RPMI 1640 medium containing 10% FBS without antibiotics. After cultivation for 24 h, the cells were stimulated with CG. Gene-knockdown effects were evaluated via western blot analysis.
Insulin-like growth factor-1 quantification. The concentrations of free IGF-1 within conditioned media were determined using Comparison of the inhibitory effects of various tested agents on CG-induced MCF-7 cell aggregation. The degree of cell aggregation was quantified using a cell-aggregation assay. Cells were incubated with CG (40 nM) and respective inhibitors (OSI-906, 10 lM; axitinib, 10 lM; sunitinib, 5 lM; vandetanib, 10 lM; pazopanib, 10 lM; sorafenib, 5 lM) for 24 h and then washed, following which the residual cells were stained with crystal violet. The results are expressed as means AE SD (n = 3); *P < 0.05, **P < 0.001, Student's t-test. (c) OSI-906 and multikinase inhibitors did not affect the enzymatic activity of CG. The enzymatic activity of CG was analyzed by measuring the rate of 4-nitroanilide release after incubation of N-succinyl-Ala-Ala-Pro-Phe p-nitroanilide with CG (40 nM) and the respective inhibitors (OSI-906, 10 lM; axitinib, 10 lM; sunitinib, 5 lM; vandetanib, 5 lM; erlotinib, 10 lM; pazopanib, 10 lM; sorafenib, 5 lM). The results are expressed as means AE SD (n = 3).
an IGF-1 ELISA Kit (R&D Systems) under denaturing conditions. To protect the released IGF-1 and IGF-binding proteins (IGFBP) from degradation by CG, a protease-inhibitor cocktail (Sigma) was added to the harvested conditioned media.
Statistical analysis. Data were analyzed using Student's t-test and are expressed as means AE SD, unless indicated otherwise. P < 0.05 was considered statistically significant for all tests.
Results
Receptor tyrosine kinase inhibitors and an insulin-like growth factor-1 receptor inhibitor suppress cathepsin G-induced MCF-7 cell aggregation. To characterize the intracellular signaling associated with CG-induced aggregation of MCF-7 cells, we screened for aggregation-inhibiting agents using the SCADS Inhibitor Kit 4, which contains 79 compounds comprising molecular-targeting anticancer drugs, including receptor tyrosine kinase inhibitors; we screened this particular library because cell migration, focal adhesion remodeling and actin rearrangement are frequently activated by extracellular stimuli, such as chemokines and growth factors. (31) (32) (33) (34) (35) The inhibitory effects of these agents on CG-induced cell aggregation were evaluated based on morphological criteria (Fig. S1 ). MCF-7 cells formed spherical multicellular aggregates after incubation with 40 nM CG for 24 h. Notably, 10 and 24 compounds in the library yielded strong and moderate inhibition of this aggregation, respectively (Table S1 ). Intriguingly, 11 of these 34 compounds target receptor tyrosine kinases, indicating that activation of these molecules is associated with CG-induced cell aggregation.
Next, we precisely characterized the inhibitory effects of six receptor tyrosine kinase inhibitors that apparently suppressed cell aggregation in the initial screen. Treatment with 2.5 nM CG for 24 h led to the formation of cell aggregates that adhered to the culture substrate on the plate, whereas treatment with 40 nM CG resulted in the formation of spheroids that floated in the medium (Fig. 1a) . Meanwhile, OSI-906, axitinib and sunitinib, markedly suppressed the cell aggregation induced by 2.5 nM CG and the spheroid formation stimulated by 40 nM CG (Fig. 1a) . Conversely, treatment with vandetanib and pazopanib resulted in only slight decreases in these effects, but increases in the number of adhering elliptical cell aggregates induced by 40 nM CG, while treatment with sorafenib had little inhibitory effect on CG-induced cell aggregation or spheroid formation. OSI-906 is a specific inhibitor of IGF-1R and insulin receptor, (36) whereas the multikinase inhibitors, axitinib, sunitinib, vandetanib, pazopanib and sorafenib target various receptor tyrosine kinases and intracellular tyrosine kinases. (37) (38) (39) (40) (41) (42) (43) (44) (45) To quantify the inhibitory effect of these compounds, we performed cell-aggregation assays (Fig. 1b) . Treatment of cells with OSI-906, axitinib and sunitinib blocked cell detachment by >50%, as compared with vehicle treatment, while vandetanib and pazopanib, and sorafenib yielded moderate and weak inhibition of CG-induced cell detachment, respectively. Notably, while CG enzymatic activity is essential for the induction of cell aggregation, (29) none of these six compounds affected this activity (Fig. 1c) . In addition to OSI-906 and the multikinase inhibitors, several other inhibitors in the compound library (anisomycin, PAC-1, TMPyP4, retinoids and inhibitors of mammalian target of rapamycin [mTOR]) partially suppressed CG-induced cell aggregation (Table S1 ). Of these, anisomycin induces cell stress by inhibiting protein synthesis, (46) PAC-1 triggers apoptosis by cleaving procaspase-3 to caspase-3 in cancer cells, (47) and TMPyP4 is a telomerase inhibitor that stabilizes DNA G-quadruplexes. (48) In addition, the retinoid complex and its receptor act as a transcription factor by binding to the retinoic acid-binding element, resulting in the transcriptional regulation of a myriad of genes. (49) Thus, our results indicate that CG-induced cell aggregation might require normal cellular homeostasis and protein turnover. Moreover, they strongly support the conclusion that this process involves the activation of intracellular signaling, and not merely the hydrolysis of adhesion-associated molecules. Finally, they suggest that activation of certain receptor tyrosine kinases is involved in CG-induced cell aggregation, and that this activation occurs independent of the enzymatic activity of CG.
Cathepsin G activates insulin-like growth factor-1 receptor and its downstream signaling in MCF-7 cells. Next, we identified the receptor tyrosine kinases whose phosphorylation is stimulated by CG in MCF-7 cells. In the human genome, 58 genes encoding receptor tyrosine kinases have been identified, and these kinases are distributed into 20 subfamilies. (34, 50) To comprehensively analyze the receptor tyrosine kinases that are phosphorylated in response to CG stimulation, we used Proteome Profiler Phospho-RTK antibody arrays, which enable the detection of tyrosine phosphorylation of 49 receptor tyrosine kinases (www.rndsystems.com). The results of these analyses indicated that CG treatment stimulated phosphorylation of IGF-1R and insulin receptor (Fig. 2a, Spots 1 and 2) . In particular, the phosphorylation of insulin receptor was weaker than that of IGF-1R, indicating that CG primarily induces the phosphorylation of IGF-1R; because these two receptors and their ligands are highly homologous, insulin receptor is likely crossactivated by IGF-1, with a lower affinity than for IGF-1R. (51, 52) We therefore focused on IGF-1R for subsequent experiments. First, we confirmed the observed phosphorylation of IGF-1R through a combination of immunoprecipitation and western blot analyses (Fig. 2b) . Moreover, although multikinase inhibitors inhibited CG-induced cell aggregation (Fig. 1a,  b) , we did not detect phosphorylation of other receptor tyrosine kinases (Fig. 2a) , suggesting that the multikinase inhibitormediated suppression of cell aggregation potentially occurred through targeting of IGF-1R.
Next, we confirmed the activation of downstream signaling of IGF-1R by CG. Binding of IGF-1 to results in autophosphorylation of IGF-1R within the intracellular domain, followed by recruitment of substrates such as IRS-1 and Srchomology/collagen protein (SHC); this, in turn, results in the stimulation of diverse intracellular pathways, such as the phosphatidylinositol 3-kinase (PI3K)/Akt and MAPK signaling pathways. (33, 51, (53) (54) (55) (56) PI3K/Akt signaling plays a crucial role in cell survival and antiapoptosis, whereas the MAPK pathway regulates cell proliferation. Notably, CG treatment induced the phosphorylation of both Akt and Erk1/2 in MCF-7 cells (Fig. 2c) . Together, these data indicate that CG activates IGF-1R and its downstream signaling.
In addition to MCF-7 cells, CG also induced aggregation of the breast cancer cell line T47D, which expresses IGF-1R, (57) and this aggregation was suppressed by OSI-906 (Fig. S2a,b) . Furthermore, CG activated the tyrosine phosphorylation of IGF-1R in T47D cells (Fig. S2c) . These results indicate that CGinduced cell aggregation might be universal among and specific to IGF-1R-positive and E-cadherin-positive breast cancer cells.
Insulin-like growth factor-1 receptor activation is required for cathepsin G-induced cell aggregation. Given the aforementioned results, we investigated whether IGF-1R signaling is required for CG-induced cell aggregation. IGF-1 signaling modulates cell motility and cell-cell adhesion in association with adhesion complexes in MCF-7 cells. (56, (58) (59) (60) Indeed, IGF-1 stimulation resulted in increased filopodia formation, cell migration and tight intercellular adhesion, but did not induce the formation of cell spheroids in MCF-7 cells. (57) To evaluate the association between IGF-1R activation and cell aggregation, we performed cell-aggregation assays using MCF-7 cells in which IGF-1R was downregulated through siRNA transfection. To avoid off-target effects, we used two hIGF1R-specific siRNA that target distinct sequences within the human IGF-1R mRNA; both siRNA reduced IGF-1R protein expression by 95% (Fig. 3a) . Notably, treatment of cells with these siRNA resulted in attenuation of the cell aggregation induced by 2.5 nM CG, as well as the spheroid formation stimulated by 40 nM CG (Fig. 3b,c) . However, despite the 95% decrease in IGF-1R protein expression in IGF-1R siRNA-transfected cells, morphological analysis showed that these cells exhibited slight aggregation upon treatment with 40 nM CG (Fig. 3b) . These data, as well as those of a previous study, (30) support the hypothesis that the cell aggregation-inducing activity of CG results from a combination of activation of IGF-1 signaling and hydrolysis of adhesion molecules, and that the CG-induced cell detachment that is accompanied by spheroid formation is caused by the hydrolysis of adhesion molecules.
Similar to siRNA-mediated IGF-1R knockdown, neutralization of IGF-1R using a monoclonal antibody specific to the extracellular domain of IGF-1R resulted in reduced CGinduced cell aggregation and spheroid formation (Fig. 4a,b) .
It was previously reported that IGF-1R regulates intercellular adhesion, in correlation with the level of E-cadherin expression, in several types of breast cancer cell lines. (59) (60) (61) Here, we confirmed that transfection of IGF-1R siRNA or treatment with neutralizing antibodies specific to IGF-1R and IGF-1 did not affect E-cadherin expression in MCF-7 cells (Fig. S3) . Thus, we conclude that IGF-1R activation is associated with the cell aggregation induced by CG.
Insulin-like growth factor-1 receptor activation induced by cathepsin G was mediated by autocrine/paracrine signaling by insulin-like growth factor-1 released from MCF-7 cells. Our results suggested that CG stimulates IGF-1 release from MCF-7 cells, the binding of which activates IGF-1R. To confirm this mechanism, we measured the amounts of IGF-1 present in conditioned media harvested from CG-treated cells. In addition, the free form of IGF-1 was measured under non-denaturing conditions because approximately 98% of IGF-1 is bound to IGFBP, which interact with IGF-1 within circulating blood and in the cellular microenvironment, thereby disrupting the binding of IGF-1 by IGF-1R. (51, 62) The amount of free IGF-1 in the medium was elevated at 4 h after CG addition, but was slightly reduced at 24 h post-stimulation (Fig. 5a) . Meanwhile, neutralization of IGF-1 using an anti-IGF-1 antibody resulted in reduced 2.5-nM CG-mediated cell aggregation (Fig. 5b) , but did not affect the spheroid formation stimulated by 40 nM CG (Fig. 5b,c) . These results indicate that direct activation of IGF-1R by IGF-1 is associated with the cell aggregation induced by 2.5 nM CG, but not the spheroid formation by 40 nM CG. Thus, we conclude that CG-induced MCF-7 cell aggregation is partially mediated by autocrine/ paracrine IGF-1 signaling. Collectively, our results support the conclusion that CG activates IGF-1 signaling and that this signaling is required for CG-induced cell aggregation.
Discussion
In this study, we revealed that CG induces IGF-1 release, and that IGF-1R and activation of its downstream signaling is required for MCF-7 cell aggregation. IGF signaling is widely recognized to regulate not only energy metabolism and growth in normal tissues, but also cell proliferation, antiapoptosis and metastasis in tumors. (51, 52, 55, (63) (64) (65) (66) Advanced breast-cancer cells were found to exhibit higher IGF-1R expression, autophosphorylation and kinase activity than benign breast tumors and normal mammary epithelia. (51, 55, 67) With respect to cell proliferation and antiapoptosis, overactivation of IGF-1 signaling strongly correlates with tumor progression in cancer development. The induction of IGF-1R activation and downstream signaling by CG suggests that this factor could accelerate cancer progression through an enhancement of cell proliferation; however, we confirmed that CG stimulation does not affect cell proliferation. (25) In contrast to the function of IGF-1R in promoting cell proliferation and survival, the roles of IGF-1R in tumor metastasis remain incompletely understood; however, IGF-1 signaling was shown to modulate cell motility and cell-cell adhesion in association with adhesion complexes in MCF-7 cells. (56, (58) (59) (60) Moreover, IGF-1 treatment and IGF-1R overactivation increased E-cadherin-mediated intercellular adhesion and spheroid formation in MCF-7 cells during cultivation on semi-solid agar. (59, 61) Interestingly, the role of IGF-1R in the regulation of intercellular adhesion appears to correlate with the level of E-cadherin expression in breast tumors. (59) (60) (61) MCF-7 cells express estrogen receptor (ER), progesterone receptor and E-cadherin, and are, therefore, considered highly differentiated breast cancer cells. Notably, this differentiation results in a reduction in the metastatic phenotype in intact MCF-7 cells. (68) E-cadherinnegative and ER-negative MDA-MB-231 breast cancer cells, which exhibit a highly metastatic phenotype, express a higher level of IGF-1R protein than do MCF-7 cells, (69) and the expression of exogenous IGF-1R in MDA-MB-231 cells enabled the formation of small multicellular aggregates. Meanwhile, overexpression of both IGF-1R and E-cadherin allowed the cells to form larger aggregates than those of parental MDA-MB-231 cells. (61) We found that CG induces cell detachment but does not stimulate cell migration (25) or aggregation in MDA-MB-231 cells (unpublished observation). Therefore, the observation that CG enhances cell motility and intercellular adhesion through IGF-1R activation is supported by these reports. In contrast, loss of E-cadherin caused dedifferentiation and invasiveness in epithelial breast cancers. (70, 71) Furthermore, in vitro invasion assay analyses using embryonic chick heart fragments indicated that the invasive potential of aggregated IGF-1R-overexpressing MCF-7 cells, which were formed by cultivating cells on semi-solid agar, was markedly lower than that of the parental cells. (59, 72) However, these reports do not entirely support the view that the enhancement of cell-cell adhesion by IGF-1R activation exerts anti-metastatic effects, as results obtained through the in vitro invasion assay using embryonic chick heart fragment differed from those of the in vivo; for example, angiogenesis in response to VEGF did not occur in the in vitro model. Notably, IGF-1 has been shown to stimulate angiogenesis, in part through the upregulation of vascular VEGF expression. (73) IGF-1 and IGF-2 induced lymphangiogenesis through a vascular endothelial growth factor receptor (VEGFR) 3-independent mechanism in an in vivo mouse cornea assay, and significantly stimulated proliferation and migration of primary lymphatic endothelial cells in an in vitro assay. (74) We expect that CG accelerates breast tumor metastasis because CG induces not only IGF-1R activation, but also the degradation of adhesion molecules and ECM, suggesting that CG might facilitate the intravasation of tumor aggregates that results from the hydrolysis of adhesion molecules and ECM, and the stimulation of angiogenesis by VEGF and lymphangiogenesis in response to IGF-1 in vivo.
Insulin-like growth factor-1 bioavailability is modulated by IGFBP in the blood and the cellular microenvironment. (51, 60) Approximately 98% of IGF-1 is bound to IGFBP in the blood, and the half-life of IGF-1 is regulated by the cleavage of IGFBP. IGFBP cleavage is mediated by several proteases, including kallikreins, MMP, NE and CG, resulting in the release of free IGF-1. We propose that the elevation in IGF-1 concentration observed in response to CG is caused by the proteolysis of IGFBP, as Gibson and Cohen showed that CG hydrolyzes IGFBP, but not IGF-1, after stimulation for at least 90 min. (75) Intriguingly, this group also demonstrated that NE, a serine protease that shares a high level of sequence homology with CG, degrades both IGFBP and IGF-1 to undetectable levels after stimulation for 20 min. Thus, in contrast to CG, NE might not increase IGF-1 concentrations because NE degrades both IGFBP and IGF-1; therefore, NE might not evoke cell migration and aggregation in MCF-7 cells. We are currently testing these hypotheses.
Curiously, while the phosphorylation of Akt and Erk evoked by CG peaked at 60 and 15 min, respectively, and decreased thereafter, the levels of IGF-1 within the conditioned medium reached a peak at 4 h (Fig. 2c and 5a and Fig. S4 ). Therefore, we expect that the immediate activation of IGF-1R signaling results from the elevation of free IGF-1 in the vicinity of the cell surface upon release from membrane-bound IGFBP digested by CG.
In summary, we provide the first evidence that CG activates IGF-1R by stimulating IGF-1 release from MCF-7 cells, and that IGF-1R activation is required for CG-induced cell aggregation. However, our results also indicate that IGF-1 signaling contributes only partially to the cell aggregation phenotype observed in response to CG, suggesting that another mechanism is involved in this process.
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